[1]
|
J. Delay, P. Pichot, T. Lemperiere, B. Elissalde and F. Peigne, “A Non-Phenothiazine and Non-Reserpine Major Neuroleptic, Haloperidol, in the Treatment of Psychoses,” Annales Medico-Psychologiques, Vol. 118, No. 1, 1960, pp. 145-152.
|
[2]
|
M. J. Bhanushali and P. J. Tuite, “The Evaluation and Management of Patients with Neuroleptic Malignant Syndrome,” Neurologic Clinics, Vol. 22, No. 2, 2004, pp. 389-411. doi:10.1016/j.ncl.2003.12.006
|
[3]
|
K. J. McAllen and D. R. Schwartz, “Adverse Drug Reactions Resulting in Hyperthermia in the Intensive Care Unit,” Critical Care Medicine, Vol. 38, 2010, pp. S244-S252. doi:10.1097/CCM.0b013e3181dda0d4
|
[4]
|
J. R. Strawn, P. E. Keck Jr. and S. N. Caroff, “Neuroleptic Malignant Syndrome,” The American Journal of Psychiatry, Vol. 164, No. 6, 2007, pp. 870-876.
doi:10.1176/appi.ajp.164.6.870
|
[5]
|
M. C. Borovicka, L. C. Bond and K. M. Gaughan, “Ziprasidoneand Lithium-Induced Neuroleptic Malignant Syndrome,” The Annals of Pharmacotherapy, Vol. 40, No. 1, 2006, pp. 139-142. doi:10.1345/aph.1G470
|
[6]
|
D. P. Seitz and S. S. Gill, “Neuroleptic Malignant Syndrome Complicating Antipsychotic Treatment of Delirium or Agitation in Medical and Surgical Patients: Case Reports and a Review of the Literature,” Psychosomatics, Vol. 50, No. 1, 2009, pp. 8-15.
doi:10.1176/appi.psy.50.1.8
|
[7]
|
M. Paul, S. G. Michael, S. John and R. J. Lenox, “An Atypical Presentation of Neuroleptic Malignant Syndrome: Diagnostic Dilemma in a Critical Care Setting,” Respiratory Care, Vol. 57, No. 2, 2011, pp. 315-317.
|
[8]
|
L. S. Picard, S. Lindsay, J. R. Strawn, R. M. Kaneria, N. C. Patel and P. E. Keck Jr., “Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations,” Pharmacotherapy, Vol. 28, 2008, pp. 530-535.
doi:10.1592/phco.28.4.530
|
[9]
|
R. J. Gurrera, S. N. Caroff, A. Cohen, et al., “An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method,” The Journal of Clinical Psychiatry, Vol. 72, No. 9, 2011, pp. 1222-1228. doi:10.4088/JCP.10m06438
|
[10]
|
V. P. Kontaxakis, B. J. Havaki-Kontaxaki, S. S. Stamouli and G. N. Christodoulou, “Toxic Interaction between Risperidone and Clozapine: A Case Report,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 26, No. 2, 2002, pp. 407-409.
doi:10.1016/S0278-5846(01)00257-3
|
[11]
|
M. Nakamura, H. Yasunaga, H. Miyata, T. Shimada, H. Horiguchi and S. Matsuda, “Mortality of Neuroleptic Malignant Syndrome Induced by Typical and Atypical Antipsychotic Drugs: A Propensity-Matched Analysis from the Japanese Diagnosis Procedure Combination Database,” The Journal of Clinical Psychiatry, 2011.
|
[12]
|
J. N. Trollor, X. Chen and P. S. Sachdev, “Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs,” CNS Drugs, Vol. 23, No. 6, 2009, pp. 477492. doi:10.2165/00023210-200923060-00003
|
[13]
|
S. N. Caroff, H. Rosenberg, S. C. Mann, E. C. Campbell and K. A. Sullivan, “Neuroleptic Malignant Syndrome in the Critical Care Unit,” Indian Journal of Critical Care Medicine, Vol. 10, No. 1, 2002, pp. 50-52.
|
[14]
|
L. Justin-Besancon and C. Laville, “Antiemetic Action of Metoclopramide with Respect to Apomorphine and Hydergine,” Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, Vol. 158, 1964, pp. 723-727.
|
[15]
|
H. P. Rang, M. M. Dale, J. M. Ritter and P. K. Moore, “Pharmacology,” 5th Edition, Churchill Livingstone, Edinburgh, 2003.
|
[16]
|
M. Tonini, S. M. Candura, E. Messori and C. A. Rizzi, “Therapeutic Potential of Drugs with Mixed 5-HT4 Agonist/5-HT3 Antagonist Action in the Control of Emesis,” Pharmacological Research: The Official Journal of the Italian Pharmacological Society, Vol. 31, No. 5, 1995, pp. 257-260.
|
[17]
|
M. Akmal and S. G. Massry, “Reversible Hepatic Dysfunction Associated with Rhabdomyolysis,” American Journal of Nephrology, Vol. 10, 1990, pp. 49-52.
doi:10.1159/000168053
|
[18]
|
A. L. Huerta-Alardin, J. Varon and P. E. Marik, “Benchto-Bedside Review: Rhabdomyolysis—An Overview for Clinicians,” Critical Care, Vol. 9, 2005, pp. 158-169.
doi:10.1186/cc2978
|
[19]
|
K. Weibrecht, M. Dayno, C. Darling and S. B. Bird, “Liver Aminotransferases Are Elevated with Rhabdomyolysis in the Absence of Significant Liver Injury,” Journal of Medical Toxicology, Vol. 6, No. 3, 2010, pp. 294-300. doi:10.1007/s13181-010-0075-9
|
[20]
|
G. C. Karmakar and R. Roxburgh, “Rhabdomyolysis in a Glue Sniffer,” The New Zealand Medical Journal, Vol. 121, No. 1271, 2008, pp. 70-71.
|
[21]
|
K. C. Kao, Y. H. Tsai, M. C. Lin, C. C. Huang, C. Y. Tsao and Y. C. Chen, “Hypokalemic Muscular Paralysis Causing Acute Respiratory Failure due to Rhabdomyolysis with Renal Tubular Acidosis in a Chronic Glue Sniffer,” Journal of Clinical Toxicology, Vol. 38, 2000, pp. 679-681. doi:10.1081/CLT-100102021
|